A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis - Wikidata - awgldk - TriplyDB

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

http://www.wikidata.org/entity/Q29616119

about

Laminin-411 is a vascular ligand for MCAM and facilitates TH17 cell entry into the CNS Neurodegeneration in multiple sclerosis: novel treatment strategies New and emerging disease modifying therapies for multiple sclerosis Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis Multiple Sclerosis: Where Will We Be in 2020?Sodium channel blockers for neuroprotection in multiple sclerosis Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Sodium channel blockers for neuroprotection in multiple sclerosis Intravenous immunoglobulin to prevent relapses during pregnancy and postpartum in multiple sclerosis Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Natalizumab for relapsing remitting multiple sclerosis Natalizumab for relapsing remitting multiple sclerosis Natalizumab for induction of remission in Crohn's disease Natalizumab for induction of remission in Crohn's disease Intravenous immunoglobulins for multiple sclerosis Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis Depressogenic effects of medications: a review Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study The role of the CD58 locus in multiple sclerosis Natalizumab: A new treatment for relapsing remitting multiple sclerosis Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy CNS Remyelination and the Innate Immune System Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations The challenge of comorbidity in clinical trials for multiple sclerosis Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis Integrin-based therapeutics: biological basis, clinical use and new drugs Hepatic manifestations of non-steroidal inflammatory bowel disease therapy The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes Disease-modifying treatments for multiple sclerosis - a review of approved medications Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis Infection as an Environmental Trigger of Multiple Sclerosis Disease Exacerbation Newer therapies for multiple sclerosis Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities

P2860

Q21090888-032F7DD7-984A-4BB9-A8DE-2D28AB52687A Q22241472-47D7D25C-DF99-48A9-956C-3E8BFECB74F0 Q22242305-D5FC87AC-B55C-4A34-B61B-8BB363381A6D Q22252598-F92AEE70-908A-425C-A0C4-E02A05C3E5B6 Q22252863-0F13E2C6-89D9-4F3A-9A0C-FA662A1DF5F2 Q24186448-24DD7D3A-9E92-4356-BED5-D4F3681FA79D Q24187126-82DC9BA6-7DBA-4E72-BBC4-81CF91BA6B69 Q24200461-D804504B-0AFE-46B1-B0BF-08442FE7BF65 Q24201599-7CABDDC2-EE51-4504-9202-A2356559A4B9 Q24202108-504884A7-3F29-4908-9AB5-5A23EEE43937 Q24235861-2A8FB2DA-D804-437A-899D-1961001F05ED Q24241982-5F648E3E-318E-43BA-BBD1-0158CD7AB94F Q24245190-5BBEAB2F-164C-4F86-B0A8-92C48A92C91D Q24246262-93ECAA93-C7CE-4DA8-BE1D-DF1D2B2B2677 Q24247968-F6B5A0B5-13D5-4C69-AB20-CE76B586807F Q24288978-F6789A31-BE57-437D-9FF5-41D7461773B6 Q24597369-3557A4C3-6679-45F6-8546-1B41D4A6DABE Q24607442-ACDCCFDD-F18A-449C-AF4E-F5F06E53C2C8 Q24635465-B0CEAD14-A9DC-48AD-B756-C2B71E08AAD8 Q24643613-87CF939D-9DFF-4D37-9B95-CCBA8CB28243 Q24647794-0291EBDF-BBE8-49CC-9C20-FB94B3157067 Q24649291-F5EA17FE-C065-4661-AA30-613CCCD7719C Q24683014-F7364E86-011C-493B-B5D2-6F9B95382548 Q24683776-C82A2ACE-74BE-48E3-8950-56DB52F963D7 Q26747242-3B52AC6C-A259-4DD7-AA0D-79E1EC042609 Q26748229-7BD62256-C29A-4039-904F-00AE7CC6DC3D Q26752859-BC981DFB-D18D-47CB-99C8-E835EB45FC14 Q26765031-DCCF6F3E-DC77-42AF-BF0B-0996CD42CCDB Q26768649-CE718975-4C39-42FC-8827-0E7C7AB8B6A7 Q26770664-9A7F61B2-4627-4A96-899F-65E38B6F3DC7 Q26770818-ADACFF4D-B2CB-4732-B621-2DC372FCEECE Q26773026-F6E53AD9-9CBE-4F49-B6CF-CBE54FEAC84D Q26773684-8AAB9BB1-3E9E-4B3C-801C-826B20F7819D Q26773978-8B5AF226-787F-47CA-96EB-550F768A5448 Q26776234-BB96137C-2D50-44CE-90CB-A74343501A8D Q26777329-951485FB-231F-4D2E-9674-8F891295586E Q26777686-25B6EF36-D56F-40B0-BA53-A97E4434FC16 Q26779416-93998108-61BE-4220-BAC0-A2C4E6AFD2AE Q26779900-A11355C1-0B4A-4F4C-B31B-4C37B994F0CB Q26781389-DB5E5C82-1964-4B2E-94C8-4439F1AFA011

P2860

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

http://www.wikidata.org/entity/Q29616119

description

2006 nî lūn-bûn

@nan

2006 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մարտին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

@ast

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

@en

type

label

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

@ast

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

@en

prefLabel

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

@ast

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

@en

P1433

Q29616119-37810856-5C9F-4123-A8CD-A7DB12741829

P1476

Q29616119-E15D651F-7D95-4E9B-B908-543843EA692F

P2093

Q29616119-144C868D-DC8E-4E94-AB05-8A0646DF66B0

Q29616119-23B273F9-46E9-4CA7-990D-959ECA81A6D7

Q29616119-37ABA6C0-6B98-4031-809D-8C598D6D825F

Q29616119-4C6845BD-33CB-4ADE-846B-5E0B1191625E

Q29616119-77320332-5569-4138-8A0E-4F128D17B6D7

Q29616119-815E77D7-9DBB-472D-BC41-5BC2ED50B968

Q29616119-87379A4B-B1F3-42E1-BC34-5396698153C6

Q29616119-BFD06795-BF14-4231-8C75-C0ABC3587D46

Q29616119-C2594208-5F97-4CAD-9F23-59E6BAC04676

Q29616119-D6566DAA-A3EC-477C-90AE-10C12201F1F1

P304

Q29616119-D7739B56-3063-4E7F-8924-C1EADBA07AC8

P31

Q29616119-C7A07E00-E255-4EE5-AA37-6AEDDF1218D9

P3181

Q29616119-85E1776A-ED30-4F05-B78D-5563B61F653D

P356

Q29616119-4B8C1DF3-430E-4996-93A4-7DE5F1EDB682

P407

Q29616119-5E08DA24-856F-4242-9AE1-33ED6FCFE31E

P433

Q29616119-F5278675-30EA-43D3-9287-763E600735B6

P478

Q29616119-D3B7FEB8-CF40-4CB0-88BE-C769DEF8B910

P50

Q29616119-054491DC-94BC-41A3-B774-D91CD28DE5C0

P577

Q29616119-36C297E4-9579-47CF-AF14-A30FD1995BF2

P698

Q29616119-AE05F2ED-4FC2-40F4-BC02-DAB2F6F34F3B

P921

Q29616119-2DBD806E-A153-42D4-82A6-9585228A160B

Q29616119-4D0AF554-14B3-49B0-A0E5-3E962D76AA35

P3181

P356

P1433

The New England Journal of Medicine

P1476

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

@en

P2093

Havrdova E

http://www.w3.org/2001/XMLSchema#string

Hutchinson M

http://www.w3.org/2001/XMLSchema#string

Kappos L

http://www.w3.org/2001/XMLSchema#string

Lublin FD

http://www.w3.org/2001/XMLSchema#string

Lynn F

http://www.w3.org/2001/XMLSchema#string

Miller DH

http://www.w3.org/2001/XMLSchema#string

O'Connor PW

http://www.w3.org/2001/XMLSchema#string

Panzara MA

http://www.w3.org/2001/XMLSchema#string

Phillips JT

http://www.w3.org/2001/XMLSchema#string

Polman CH

http://www.w3.org/2001/XMLSchema#string

P304

899-910

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

121607

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA044397

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

354

http://www.w3.org/2001/XMLSchema#string

P50

Gavin Giovannoni

P577

2006-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16510744

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis